{"nctId":"NCT01408576","briefTitle":"Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus","startDateStruct":{"date":"2011-07"},"conditions":["Systemic Lupus Erythematosus"],"count":1250,"armGroups":[{"label":"Epratuzumab 600 mg per week","type":"EXPERIMENTAL","interventionNames":["Drug: Epratuzumab"]},{"label":"Epratuzumab 1200 mg every other week","type":"EXPERIMENTAL","interventionNames":["Drug: Epratuzumab"]}],"interventions":[{"name":"Epratuzumab","otherNames":[]},{"name":"Epratuzumab","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject has completed the double-blind study SL0009 (NCT01262365) or SL0010 (NCT01261793) or terminated prematurely at Week 16 or later in SL0009 or SL0010 due to lack of efficacy and would, in the opinion of the investigator, continue to benefit from continued epratuzumab treatment\n* Subject has completed open-label study SL0006 (NCT00383513) or SL0008 (NCT00660881), and would, in the opinion of the investigator, continue to benefit from continued epratuzumab treatment\n* Women of childbearing potential must agree to use an acceptable method of birth control\n\nExclusion Criteria:\n\n* Subjects with active, severe, neuropsychiatric SLE, defined as any neuropsychiatric element scoring British Isles Lupus Assessment Group Index (BILAG) level A disease\n* Subjects with active, severe SLE disease activity which involves the renal system\n* Subjects with concurrent relevant medical conditions like defined chronic infections or high risk of new significant infections\n* Substance abuse or dependence\n* History of malignant cancer\n* Subjects with any other condition which, in the investigator's judgment, would make the subject unsuitable for inclusion","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects Prematurely Discontinuing Due to a Treatment-emergent Adverse Event (TEAE) During the Treatment Period (Maximum 96 Weeks)","description":"A TEAE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"45","spread":null},{"groupId":"OG002","value":"25","spread":null},{"groupId":"OG003","value":"51","spread":null},{"groupId":"OG004","value":"96","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Subjects Prematurely Discontinuing Due to a Treatment-emergent Adverse Event (TEAE) During the Treatment Period (Maximum 96 Weeks)","description":"A TEAE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.7","spread":null},{"groupId":"OG001","value":"9.1","spread":null},{"groupId":"OG002","value":"4.9","spread":null},{"groupId":"OG003","value":"6.8","spread":null},{"groupId":"OG004","value":"7.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Reporting at Least 1 Serious Adverse Event (SAE) During the Treatment Period (Maximum 96 Weeks)","description":"A SAE is a treatment-emergent adverse event (TEAE) that the investigator classifies as serious. This includes:\n\n* Death\n* Life-threatening\n* Significant or persistent disability/incapacity\n* Congenital anomaly/birth defect (including that occurring in a fetus)\n* Important medical event that, based upon appropriate medical judgment, may jeopardize the patient or subject and may require medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious\n* Initial inpatient hospitalization or prolongation of hospitalization","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"119","spread":null},{"groupId":"OG002","value":"104","spread":null},{"groupId":"OG003","value":"185","spread":null},{"groupId":"OG004","value":"304","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Subjects Reporting at Least 1 Serious Adverse Event (SAE) During the Treatment Period (Maximum 96 Weeks)","description":"A SAE is a treatment-emergent adverse event (TEAE) that the investigator classifies as serious. This includes:\n\n* Death\n* Life-threatening\n* Significant or persistent disability/incapacity\n* Congenital anomaly/birth defect (including that occurring in a fetus)\n* Important medical event that, based upon appropriate medical judgment, may jeopardize the patient or subject and may require medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious\n* Initial inpatient hospitalization or prolongation of hospitalization","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.2","spread":null},{"groupId":"OG001","value":"23.9","spread":null},{"groupId":"OG002","value":"20.5","spread":null},{"groupId":"OG003","value":"24.6","spread":null},{"groupId":"OG004","value":"24.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Meeting Treatment Response Criteria According to a Combined Response Index","description":"Combined response index is a response variable (yes/no) incorporating the following criteria for achievement of responder status (ie, all criteria must be met to achieve responder status): (1) British Isles Lupus Activity Group (BILAG) improvement, (2) No worsening in Systemic Lupus Erythematosus Activity Index (SLEDAI), (3) No worsening in Physician's Global Assessment of Disease, and (4) No disallowed changes in concomitant medications, with disallowed changes including mainly increases in corticosteroids, immunosuppressants, and antimalarials.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null},{"groupId":"OG001","value":"146","spread":null},{"groupId":"OG002","value":"134","spread":null},{"groupId":"OG003","value":"216","spread":null},{"groupId":"OG004","value":"362","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Meeting Treatment Response Criteria According to a Combined Response Index","description":"Combined response index is a response variable (yes/no) incorporating the following criteria for achievement of responder status (ie, all criteria must be met to achieve responder status): (1) British Isles Lupus Activity Group (BILAG) improvement, (2) No worsening in Systemic Lupus Erythematosus Activity Index (SLEDAI), (3) No worsening in Physician's Global Assessment of Disease, and (4) No disallowed changes in concomitant medications, with disallowed changes including mainly increases in corticosteroids, immunosuppressants, and antimalarials.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.7","spread":null},{"groupId":"OG001","value":"29.9","spread":null},{"groupId":"OG002","value":"27.1","spread":null},{"groupId":"OG003","value":"29.8","spread":null},{"groupId":"OG004","value":"29.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Meeting Treatment Response Criteria According to a Combined Response Index","description":"Combined response index is a response variable (yes/no) incorporating the following criteria for achievement of responder status (ie, all criteria must be met to achieve responder status): (1) British Isles Lupus Activity Group (BILAG) improvement, (2) No worsening in Systemic Lupus Erythematosus Activity Index (SLEDAI), (3) No worsening in Physician's Global Assessment of Disease, and (4) No disallowed changes in concomitant medications, with disallowed changes including mainly increases in corticosteroids, immunosuppressants, and antimalarials.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"78","spread":null},{"groupId":"OG003","value":"152","spread":null},{"groupId":"OG004","value":"218","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percent of Subjects Meeting Treatment Response Criteria According to a Combined Response Index","description":"Combined response index is a response variable (yes/no) incorporating the following criteria for achievement of responder status (ie, all criteria must be met to achieve responder status): (1) British Isles Lupus Activity Group (BILAG) improvement, (2) No worsening in Systemic Lupus Erythematosus Activity Index (SLEDAI), (3) No worsening in Physician's Global Assessment of Disease, and (4) No disallowed changes in concomitant medications, with disallowed changes including mainly increases in corticosteroids, immunosuppressants, and antimalarials.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.8","spread":null},{"groupId":"OG001","value":"21.6","spread":null},{"groupId":"OG002","value":"26.2","spread":null},{"groupId":"OG003","value":"31.4","spread":null},{"groupId":"OG004","value":"27.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":81,"n":244},"commonTop":["Upper respiratory tract infection","Urinary tract infection","Headache","Nausea","Nasopharyngitis"]}}}